MTBC Gene Atlas

Drug-resistance tester

Predict anti-tuberculosis drug resistance for an MTBC strain. Give an SRA accession, paste its variants (SPDI or VCF), or test a single mutation. Matching is reconciled across representations (SNP, MNV, indel), so blind spots such as the gyrA fluoroquinolone MNV are caught.

Research tool, not a clinical diagnostic. Verdicts come only from catalogued mutation–resistance associations (WHO catalogue of mutations, 2nd ed. 2023, with tb-profiler and CRyPTIC empirical signal). The absence of a determinant is not evidence of susceptibility, and this output must not be used to guide treatment.
Catalogue: 4255 R-associated determinants · 15 drugs.
Try

Method & sources

  • Catalogue: WHO Catalogue of mutations in Mycobacterium tuberculosis complex (2nd ed., 2023), consolidated with the tb-profiler reference database and CRyPTIC empirical signal. Only R-associated determinants drive a verdict.
  • Matching: reconciled at the variant-representation level (SNP exact, MNV decomposition into component SNPs, indel exact) to avoid the systematic under-call of a raw SPDI equality.
  • SRA resolution: variants of an accession are fetched on demand from the TBannotator database; coverage depends on whether the accession has been annotated there.
  • Scope: deterministic catalogue baseline. A lineage-stratified machine-learning residual layer is planned but not yet served here.
  • Companion: for the gene-level functional annotation of any locus, see the gene atlas.